Aptorum Group Limited
APM · NASDAQ
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Aptorum Group Limited (APM) is a global biotechnology company focused on the development of new drug candidates for the treatment of various diseases. Their research targets the treatment of infectious diseases, neurological and gastrointestinal disorders, oncological diseases, and other serious health conditions. Aptorum Group focuses on innovative therapeutic approaches, including the use of AI and bioinformatics technologies to discover new drug targets and therapies. The company is also active in the development of herbal-based medicines and traditional healing practices. Their aim is to bring innovative and effective therapeutic approaches to improve the health of patients worldwide. Aptorum Group Limited (APM) shares could be suitable for investors seeking investments in biotechnology companies with potential for innovative therapeutic development and global growth.
Sector
Healthcare
Industry
Biotechnology
CEO
Ian Huen
Employees
2
Headquarters
Princeton